ARS Pharmaceuticals, Inc.

NasdaqGM:SPRY Stock Report

Market Cap: US$1.1b

ARS Pharmaceuticals Management

Management criteria checks 3/4

ARS Pharmaceuticals' CEO is Rich Lowenthal, appointed in Jan 2015, has a tenure of 10.92 years. total yearly compensation is $7.17M, comprised of 9.1% salary and 90.9% bonuses, including company stock and options. directly owns 1.21% of the company’s shares, worth $13.74M. The average tenure of the management team and the board of directors is 3.8 years and 5.6 years respectively.

Key information

Rich Lowenthal

Chief executive officer

US$7.2m

Total compensation

CEO salary percentage9.07%
CEO tenure10.9yrs
CEO ownership1.2%
Management average tenure3.8yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating

Nov 10

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) May Have Run Too Fast Too Soon With Recent 27% Price Plummet

Aug 28
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) May Have Run Too Fast Too Soon With Recent 27% Price Plummet

ARS Pharmaceuticals (NASDAQ:SPRY) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Aug 15
ARS Pharmaceuticals (NASDAQ:SPRY) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jun 30
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Have Just Cut Their ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Revenue Estimates By 15%

May 15
Analysts Have Just Cut Their ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Revenue Estimates By 15%
User avatar

80% Coverage And Pediatric Launch Will Expand Global Markets

Rapid payer coverage expansion and pediatric market entry may enhance revenue and ease prescribing burdens with reduced authorization requirements.

Revenues Not Telling The Story For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Shares Rise 28%

Apr 03
Revenues Not Telling The Story For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Shares Rise 28%

Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term

Mar 26
Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term

ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions

Feb 06

ARS Pharmaceuticals: Demand Curve Is Key Unknown

Nov 20

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

Sep 13
We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval

Sep 06

ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles

Jun 25

We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate

Mar 18
We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate

ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

Nov 14
ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

May 12
Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

CEO Compensation Analysis

How has Rich Lowenthal's remuneration changed compared to ARS Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$80m

Jun 30 2025n/an/a

-US$48m

Mar 31 2025n/an/a

-US$16m

Dec 31 2024US$7mUS$651k

US$8m

Sep 30 2024n/an/a

-US$49m

Jun 30 2024n/an/a

-US$45m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$10mUS$620k

-US$54m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$53m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$909kUS$75k

-US$35m

Compensation vs Market: Rich's total compensation ($USD7.17M) is above average for companies of similar size in the US market ($USD3.47M).

Compensation vs Earnings: Rich's compensation has been consistent with company performance over the past year.

CEO

Rich Lowenthal (59 yo)

10.9yrs
Tenure
US$7,174,995
Compensation

Mr. Richard E. Lowenthal, also known as Rich, MS, MSEL, MBA, serves as President and Director at ARS Pharmaceuticals, Inc. since 2015 and serves as its Chief Executive Officer since 2018. He is Co-Founder...

Leadership Team

NamePositionTenureCompensationOwnership
Richard Lowenthal
Co-Founder10.9yrsUS$7.17m1.21%
$ 13.7m
Sarina Tanimoto
Co-Founder & Chief Medical Officerno dataUS$4.25m3.32%
$ 37.6m
Brian Dorsey
Chief Operating Officer7.9yrsUS$2.24m0.011%
$ 123.8k
Robert Bell
Co-Founder & Chief Science Officerno datano datano data
Kathleen Scott
Chief Financial Officer3.8yrsno data0.019%
$ 210.0k
Alexander Fitzpatrick
Chief Legal Officer & Secretary3yrsUS$5.32m0.091%
$ 1.0m
Daniel Relovsky
Senior Vice President of Marketing3.8yrsno datano data
Lynda Harris
Vice President of Human Resources1.9yrsno datano data
Justin Chakma
Chief Business Officer6.5yrsno data0%
$ 0
Harris Kaplan
Executive Vice President of Commercial Strategy3.8yrsno datano data
Eric Karas
Chief Commercial Officer3.7yrsUS$618.61k0.010%
$ 118.5k
3.8yrs
Average Tenure
56yo
Average Age

Experienced Management: SPRY's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Lowenthal
Co-Founder10.9yrsUS$7.17m1.21%
$ 13.7m
Phillip Schneider
Independent Director6.6yrsUS$297.93k0%
$ 0
Michael Kelly
Independent Director6.6yrsUS$287.93k0.084%
$ 955.4k
Pratik Shah
Chairman of the Board9.9yrsUS$542.93k4.53%
$ 51.4m
Brenton Saunders
Director4.6yrsUS$282.93kno data
Rajeev Dadoo
Independent Director4.3yrsUS$282.93k0%
$ 0
Peter Kolchinsky
Independent Director4.3yrsUS$287.93k0%
$ 0
Saqib Islam
Independent Director3.1yrsUS$287.93k0.015%
$ 175.0k
Thomas Casale
Member of Scientific Advisory Boardno datano datano data
Michael Kaliner
Member of Scientific Advisory Boardno datano datano data
Motohiro Ebisawa
Member of Scientific Advisory Boardno datano datano data
Richard Lockey
Member of Scientific Advisory Boardno datano datano data
5.6yrs
Average Tenure
55yo
Average Age

Experienced Board: SPRY's board of directors are considered experienced (5.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/26 00:45
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ARS Pharmaceuticals, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joshua SchimmerCantor Fitzgerald & Co.
Roanna Clarissa RuizLeerink Partners LLC
Andreas ArgyridesOppenheimer & Co. Inc.